Trial Profile
Tagrisso Tablets Clinical Experience Investigation (All Case Investigation)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Sep 2020
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 11 Sep 2020 Results of analysis occurrence of Interstitial Lung Disease during osimertinib use, published in the Journal of Thoracic Oncology
- 04 Aug 2020 Results assessing adverse drug reactions during real-world osimertinib use were investigated in Japan, published in the Japanese Journal of Clinical Oncology.
- 08 Oct 2018 Status changed from active, no longer recruiting to completed.